Close Menu

Quark Pharmaceuticals said this week that it has dosed the first patient in a phase I study of its siRNA-based ocular neuroprotectant QPI-1007.

In the study, the drug will be directly delivered to the eyes of legally blind patients and patients with a recent onset of non-arteritic anterior ischemic optic neuropathy, a rare condition that can lead to permanent blindness. Primary endpoints of the trial are safety and tolerability, but Quark will also evaluate whether QPI-1007 has any biological activity in NAION patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.